Not applicableNot Yet RecruitingNCT06879470What this trial is testingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LymphomaWho this might be right forB-Non Hodgkin Lymphoma He Huang 24
Early research (Phase 1)Active Not RecruitingNCT02992522What this trial is testingObinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forB-Cell Lymphoma, UnspecifiedGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+10 more Beth Christian 22
Testing effectiveness (Phase 2)Looking for participantsNCT06854653What this trial is testingPTX 100 in Patients With Relapsed/Refractory CTCLWho this might be right forCTCL Prescient Therapeutics, Ltd. 115
Early research (Phase 1)Looking for participantsNCT06445803What this trial is testingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLWho this might be right forAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionB-cell Lymphoma Refractory+1 more Rong Tao 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT03930953What this trial is testingA Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Who this might be right forLymphoma, Non-Hodgkin Celgene 438
Testing effectiveness (Phase 2)Ended earlyNCT01186458What this trial is testingFludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaWho this might be right forLymphoma, Non-Hodgkin Hoosier Cancer Research Network 4
Testing effectiveness (Phase 2)Study completedNCT00138164What this trial is testingDenileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forLymphoma Jonsson Comprehensive Cancer Center 50
Not applicableUnknownNCT05422521What this trial is testingRadiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's LymphomaWho this might be right forRefractory or Relapsed Non-Hodgkin's Lymphoma Centre Hospitalier Universitaire de Nice 20
Not applicableStudy completedNCT02139592What this trial is testingBrentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"Who this might be right forRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Takeda 292
Testing effectiveness (Phase 2)Active Not RecruitingNCT04205409What this trial is testingNivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesWho this might be right forRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more University of Washington 20
Early research (Phase 1)Study completedNCT02543879What this trial is testingStudy of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesWho this might be right forAcute Myeloid LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome+1 more Forma Therapeutics, Inc. 94
Very early researchUnknownNCT04696705What this trial is testingAllogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsWho this might be right forNon-Hodgkin's Lymphoma (NHL)Peripheral T Cell Lymphoma (PTCL) Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)Study completedNCT03770416What this trial is testingNivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaWho this might be right forCentral Nervous System B-Cell Non-Hodgkin LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System Lymphoma M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Ended earlyNCT06088654What this trial is testingPhase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaWho this might be right forNon Hodgkin Lymphoma Innate Pharma 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT05627856What this trial is testingGNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLWho this might be right forNK/T Cell LymphomaVascular Immunomother T Cell LymphomaNon-Hodgkin Lymphoma Sichuan Baili Pharmaceutical Co., Ltd. 4
Early research (Phase 1)Active Not RecruitingNCT05665062What this trial is testingAutologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesWho this might be right forCLL/SLLNHLMantle Cell Lymphoma+4 more Synthekine 36
Not applicableUnknownNCT04447547What this trial is testingClinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaWho this might be right forNon-hodgkin's Lymphoma Hebei Senlang Biotechnology Inc., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT07022964What this trial is testingCD5 CAR T-Cell Therapy for r/r T-cell LymphomasWho this might be right forT-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL) Beijing GoBroad Hospital 36
Early research (Phase 1)Study completedNCT02594384What this trial is testingA Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaWho this might be right forLymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic OrphAI Therapeutics 62
Early research (Phase 1)Study completedNCT03029338What this trial is testingCD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaWho this might be right forLymphomas Non-Hodgkin's B-CellRelapse Institute of Hematology & Blood Diseases Hospital, China 20